Financial Deals Industry Tracker: Pharmaceuticals and Healthcare August 2008 (analysis of merger and acquisition (M&A), private equity, venture financing, private placement, initial public offering (IPO), and secondary offering deals)

Financial Deals Industry Tracker: Pharmaceuticals and Healthcare August 2008 (analysis of merger and acquisition (M&A), private equity, venture financing, private placement, initial public offering (IPO), and secondary offering deals)

Synopsis

Analysis and opinion on monthly deal activity, along with the trend for the last six months for merger and acquisition (M&A), private equity, private placement, IPO, and secondary offering deals.

Introduction

This report contains extensive qualitative and quantitative analysis of monthly deal activity (including strategic alliances) in the biotechnology, healthcare services, medical devices, and pharmaceuticals sectors across global markets, with a specific focus on key emerging markets. It offers insights into deal activity, deal rationale, and valuation trends.

Scope

• Insights into deal activity across M&A, private equity, private placement, IPO, and secondary offering deals
• In-depth analysis on all key sectors, namely biotechnology, healthcare services, medical devices, and pharmaceuticals
• Geographical trends by primary regions and by key emerging markets
• Detailed analysis of the deal activity during the month, along with the trend for the last six months by deal volume and value

Highlights

• The pharmaceutical and healthcare sector recorded 92 M&A transactions worth $11.1 billion in August 2008, a decline of 24.6% and 50.6% in volume and value terms, respectively, compared with the six month (Feb 2008–Jul 2008) average. M&A activity in the biotechnology sector was aimed at expanding product pipelines.
• Healthcare retailers and distributors focused on strengthening their market positions and entering into emerging markets to drive growth. To take advantage of the growing healthcare market, private equity players increased their investments in the segment. Cross-border deals led the deal activity in the medical devices segment.
• Venture capitalists invested over $800.2m in 74 companies, a decrease of 12.9% in value terms compared with the last six-month average, driven by investments in medical devices and pharmaceutical sectors.The sector recorded nine public offerings, a decrease of 16.9% compared with the last six-month average.

Reason to Purchase

• Understand which sectors are experiencing the most activity, and which type of investor, and advisor are playing the significant roles
• Find out how key deals are changing the competitive landscape of your business
• Find out how companies in pharmaceuticals and healthcare industry are raising funds through capital markets, private equity, and private placement deals

Table of Contents

1. Introduction
a. About Financial Deals
b. About this report

2. Mergers and acquisitions (including private equity deals)
a. Monthly roundup
i. Biotechnology
ii. Healthcare services
iii. Pharmaceuticals
iv. Medical devices
b. Volume and value analysis by sector
c. Volume analysis by geography
i. Global regions (North America, Europe, Asia Pacific, and Rest of World)
ii. Emerging markets (BRIC, Middle East, Eastern Europe, Latin America, and Africa)
d. Value analysis by geography
i. Global regions (North America, Europe, Asia Pacific, and Rest of World)
ii. Emerging markets (BRIC, Middle East, Eastern Europe, Latin America, and Africa)
e. Trend analysis by deal size
f. Advisory ranking M&A (trailing six months) – financial and legal
g. Private equity firm ranking

3. Venture financing
a. Monthly roundup
b. Volume and value analysis by sector
c. Volume and value analysis by geography
d. Trend analysis by deal size
e. Venture finance firm ranking

4. Public offering

a. Monthly roundup
b. Volume and value analysis by sector
c. Volume and value analysis by geography
d. Trend analysis by deal size

5. Private placement
a. Monthly roundup
b. Volume and value analysis by sector
c. Volume and value analysis by geography
d. Trend analysis by deal size

6. Advisory ranking for all deals (trailing six months) – financial and legal

7. Appendix
a. Definition
b. Disclaimer